EUVIMEDEUVIMED entdecken
Crossref

Dual-targeting LILRB3/LILRB4 CAR-T cells for the treatment of monocytic acute myeloid leukemia

Xiaofeng Chen, Cuiyu Guo, Yongyan Tu, Xian Wei, Qiannan Ren, Hongbin Yu, Han Deng, Jialin Wu, Tian Chen, Zhixiong Zhang, Zhongguo Hu, Shengyan Zhao und 12 weitere

Biochemical Pharmacology · 2026-10 · 252 · 118253

DOI: 10.1016/j.bcp.2026.118253 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical Pharmacology, 2026-10. Verfasst von Xiaofeng Chen und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotherapy, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China. Hauptthemen laut MEDLINE: Receptors, Immunologic, Membrane Glycoproteins, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Sichuan Province Department of Science and Technology, West China Hospital of Sichuan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Monocytic acute myeloid leukemia (AML) is an aggressive malignancy associated with poor prognosis. High expression levels of LILRB3 and LILRB4 are commonly observed in monocytic AML. In this study, the expression of LILRB3 and LILRB4 was analyzed in monocytic AML patient samples, leukemic stem cell-enriched populations, and AML cell lines, revealing frequent co-expression and suggesting that a dual-targeting approach may provide enhanced therapeutic benefit. Accordingly, dual-targeting chimeric antigen receptor (CAR)-T cells were engineered using a single-chain variable fragment (scFv) derived from a humanized antibody capable of recognizing both LILRB3 and LILRB4. In vitro, LILRB3/4 CAR-T cells exhibited potent, antigen-dependent cytotoxicity against AML cell lines and primary AML blasts with minimal toxicity to normal hematopoietic stem/progenitor cells. Additionally, these CAR-T cells induced superior lysis of double-positive leukemic cells compared with single-positive populations. In both subcutaneous and systemic AML xenograft models, treatment with LILRB3/4 CAR-T cells significantly reduced tumor burden and prolonged survival. Collectively, these results demonstrate that LILRB3/4 CAR-T cells represent a promising therapeutic strategy for monocytic AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, ImmunologicMembrane GlycoproteinsImmunotherapy, AdoptiveReceptors, Chimeric AntigenLeukemia, Monocytic, AcuteHumansAnimalsMiceXenograft Model Antitumor AssaysCell Line, TumorFemaleMaleMice, SCIDMice, Inbred NODLeukemia, Myeloid, AcuteAntigens, CD

Stichwörter der Autor:innen

Acute myeloid leukemiaDual-targeting CAR-TImmunotherapyLILRB3LILRB4

Substanzen

Receptors, ImmunologicLILRB4 protein, humanMembrane GlycoproteinsLILRB3 protein, humanReceptors, Chimeric AntigenAntigens, CD

Autor:innen und Institutionen

  • Department of Biotherapy, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China.
  • Department of Hematology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China.
  • College of Medical Technology, Qujing University of Medicine & Health Sciences, Qujing 655100, Yunnan, China.
  • Frontier Innovation Center for Dental Medicine Plus, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, Sichuan, China.
  • Institute of Integrated Traditional Chinese and Western Medicine, Clinical Epidemiology and Evidence-based Medicine Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China.
  • Department of Biotherapy, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China. Electronic address: goulantu@scu.edu.cn.

Förderung

  • Sichuan Province Department of Science and Technology
  • West China Hospital of Sichuan University

Zitieren

APA

Chen, X., Guo, C., Tu, Y., Wei, X., Ren, Q., Yu, H., Deng, H., Wu, J., Chen, T., Zhang, Z., Hu, Z., Zhao, S., Zhang, G., Lai, Q., Yang, S., Zhang, Y., Cui, S., Jiang, X., Zhang, R., …, & Yang, J. (2026). Dual-targeting LILRB3/LILRB4 CAR-T cells for the treatment of monocytic acute myeloid leukemia. Biochemical Pharmacology, 252, 118253. https://doi.org/10.1016/j.bcp.2026.118253

Vancouver

Chen X, Guo C, Tu Y, Wei X, Ren Q, Yu H, et al. Dual-targeting LILRB3/LILRB4 CAR-T cells for the treatment of monocytic acute myeloid leukemia. Biochemical Pharmacology. 2026;252:118253. doi:10.1016/j.bcp.2026.118253

BibTeX
@article{Chen2026,
  author = {Chen, Xiaofeng and Guo, Cuiyu and Tu, Yongyan and Wei, Xian and Ren, Qiannan and Yu, Hongbin and Deng, Han and Wu, Jialin and Chen, Tian and Zhang, Zhixiong and Hu, Zhongguo and Zhao, Shengyan and Zhang, Guangbing and Lai, Qinhuai and Yang, Shuyun and Zhang, Yinglu and Cui, Susu and Jiang, Xiaohua and Zhang, Ruirui and Wang, Doudou and Li, Donghao and Liu, Huayi and Gou, Lantu and Yang, Jinliang},
  title = {Dual-targeting LILRB3/LILRB4 CAR-T cells for the treatment of monocytic acute myeloid leukemia},
  journal = {Biochemical Pharmacology},
  year = {2026},
  volume = {252},
  pages = {118253},
  doi = {10.1016/j.bcp.2026.118253}
}
Kostenlos starten →